Full-Time

Associate Director Global Evidence and Outcomes

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

Compensation Overview

$153.6k - $241.3k/yr

+ Short-term Incentives + Long-term Incentives

Senior, Expert

Cambridge, MA, USA

This position is classified as 'hybrid' in accordance with Takeda’s Hybrid and Remote Work policy, which implies a mix of remote and in-office work.

Category
Bioinformatics
Genomics
Public Health
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Combination of academic training and practical experience in outcomes research is required. This may consist of: Doctoral degree (e.g., Ph.D., Sc.D. or Dr P.H.) in a relevant discipline such as, but not limited to, health services research, health outcomes research, epidemiology, pharmacy administration, public health, economics, statistics or decision sciences, genetics plus 5+ years practical experience.
  • Masters degree in a related discipline (as noted above), plus 7+ years practical experience.
  • Practical experience (number of years as noted above) in performing epidemiology and outcomes research and/or computational biology, in any setting, including life sciences company, research organization, academic institution or governmental agency, is required.
  • Strong technical expertise required in design and conduct of observational studies, time to event modeling or molecular data as well as the scientific communication of study findings.
  • Ability to communicate scientific evidence, with strong written and verbal presentation skills across functions with different levels of knowledge, is required.
Responsibilities
  • Lead the design, conduct, analyses, interpretation, and communication of real-world evidence studies including complex epidemiological and outcomes research studies including genetic/ genomic data to support evidentiary needs for internal and external stakeholders for Takeda products from early development through launch and commercialization across the product lifecycle in alignment with product evidence generation plans.
  • Inform and collaborate in the design and conduct of observational studies to support clinical development of Takeda products, including development of synthetic controls.
  • Lead the selection, development, evaluation, and interpretation of clinical endpoint(s) as appropriate for asset development programs and other evidence generation programs for relevant disease areas.
  • Provide expertise and guidance on observational research in the evaluation and use of data sets with both molecular/ genetic and clinical data to analysts and other cross-functional team members.
  • Collaborate and partner internally with the GEO product lead and other functions to ensure relevant GEO studies are aligned with disease and asset strategy, as well as congruent with evidence generation plans within a multi-disciplinary Takeda framework to meet study needs.
  • Communicate scientific findings to internal and external audiences as effectively as possible.
Desired Qualifications
  • Record of high-quality, peer-reviewed publications is preferred.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline that includes 11 NMEs, with plans for up to 15 product launches by FY2024. Takeda's products are aimed at healthcare providers, hospitals, and patients around the world, and the company collaborates with about 41,000 suppliers to ensure the production and distribution of its medicines. Unlike many competitors, Takeda emphasizes patient-centric values, ensuring that the needs of patients guide its operations. Additionally, Takeda is committed to environmental sustainability, recognizing the connection between environmental health and human health. The company's goal is to provide life-changing treatments while also addressing environmental risks that could affect public health.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's focus on personalized medicine can increase treatment efficacy and patient satisfaction.
  • Expansion in Southeast Asia offers opportunities for increased market presence and revenue growth.
  • Collaborations with tech companies can accelerate R&D processes and reduce costs.

What critics are saying

  • Data breach could lead to financial and reputational damage for Takeda.
  • Antitrust litigation with Meijer may result in financial penalties or business practice changes.
  • High financial commitments in partnerships could strain resources if outcomes are not achieved.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and R&D efforts.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 product launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.